Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Debra Stories

2014-04-01 08:28:31

DURHAM, N.C., April 1, 2014 /PRNewswire/ -- Scioderm, Inc. today announced it has completed enrollment of its Phase 2b study (SD-003) to evaluate the safety and efficacy of SD-101, a novel topical therapy for the treatment of blisters and lesions in patients with Epidermolysis Bullosa (EB.) Key points: -- Epidermolysis Bullosa (EB) is a rare, genetic connective tissue disorder that typically manifests at birth or early childhood. -- All forms of EB share the common symptom...

2014-02-17 12:28:04

Marketing Campaign Kick-off Begins with New Product Launch at IMS 2014 PORTLAND, Ore., Feb. 17, 2014 /PRNewswire/ -- Debra Seifert Communications, a boutique provider of communications for high-tech companies, announced today that it has added Signal Hound to its client roster. Signal Hound designs and manufactures small USB-based spectrum analyzers that perform on par with traditional, higher-cost analyzers that come in large boxes. Signal Hound will be using Debra Seifert...

2014-01-06 08:26:03

DURHAM, N.C., Jan. 6, 2014 /PRNewswire/ -- Scioderm, Inc. today announced the initiation of a Phase 2B study designed to evaluate the efficacy and safety of SD-101, a novel topical therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a rare, genetic connective tissue disorder that typically manifests at birth or early childhood. "People affected by EB suffer skin blisters, chronic wounds, almost constant pain and itching, and scarring," said...

2013-10-30 08:31:06

DURHAM, N.C., Oct. 30, 2013 /PRNewswire/ -- Scioderm, Inc. was honored with the Partners in Progress Award from the Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA). The award recognized the company's recent work developing SD-101, which is a topical therapy being developed to treat the severe skin effects seen in patients with inherited Epidermolysis Bullosa (EB), a rare, genetic, connective tissue disorder for which there is no treatment or cure. Dr. Robert...

2013-10-21 08:29:01

DURHAM, N.C., Oct. 21, 2013 /PRNewswire/ -- Scioderm, Inc. announced the appointment of the company's Co-Founder and CEO, Dr. Robert Ryan, to the board of directors of the Dystrophic Epidermolysis Bullosa Research Association of America (DebRA). DebRA, is the only national non-profit group dedicated to funding research and providing services and programs for those with Epidermolysis Bullosa (EB). Scioderm's lead program is an investigational therapy being evaluated for the treatment...

2013-10-01 16:25:37

Honoring Sonya and Mats Wilander, Former #1 and International Tennis Hall of Fame Member NEW YORK, Oct. 1, 2013 /PRNewswire/ -- The 15th Annual debra of America Benefit will be held Thursday, October 24 from 7:30PM to 10:30PM at The Museum of Modern Art in New York City. The benefit will honor Sonya and Mats Wilander in recognition of their years of hard work after their son was born with EB. The Wilanders have been instrumental in helping debra of America raise awareness of the...

2013-08-07 16:24:09

Be Part of the Cure for "Epidermolysis Bullosa (EB) - The Worst Disease You've Never Heard Of.(TM)" NEW YORK, Aug. 7, 2013 /PRNewswire-USNewswire/ -- The Inaugural Mats Wilander Foundation Tennis Pro-Am benefiting debra of America will be held Wednesday, August 28 from 8:30 A.M. to 2 P.M. at the legendary 100-year-old West Side Tennis Club in Forest Hills, Queens, New York. West Side Tennis Club was the former site of the US Open Tennis Championships for over six decades. The event is open...

2013-03-11 23:01:05

An overworked, pudgy insomniac takes on America´s health crisis. Beginning with Kentucky, show host Debra K is walking the talk through 50 states with the launch of The Journey into Wellbeing® TV series. Delray Beach, FL (PRWEB) March 11, 2013 An overworked, pudgy insomniac takes on America´s health crisis. “Not being sick is just not good enough,” says natural health explorer Debra K. Beginning with Kentucky, Debra K is walking the talk through 50 states with the...

2013-02-13 20:21:47

RALEIGH, N.C., Feb. 13, 2013 /PRNewswire-iReach/ -- Scioderm announced that the US Food and Drug Administration (FDA) has reviewed and allowed the investigational new drug (IND) application for SD-101 to proceed. SD-101 is a topical treatment being developed for the treatment of Epidermolysis Bullosa (EB). The Company plans to initiate a Phase 1 study in the coming months, with initiation of the Phase 2B/3 study in EB patients to occur in the second half of 2013. EB is a rare genetic...

2013-02-08 08:25:25

SAN DIEGO, February 8, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US. [i] "People...